268 related articles for article (PubMed ID: 22999811)
1. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.
Buser N; Ivic S; Kessler TM; Kessels AG; Bachmann LM
Eur Urol; 2012 Dec; 62(6):1040-60. PubMed ID: 22999811
[TBL] [Abstract][Full Text] [Related]
2. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG
PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193
[TBL] [Abstract][Full Text] [Related]
3. Trospium chloride treatment of overactive bladder.
Biastre K; Burnakis T
Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
[TBL] [Abstract][Full Text] [Related]
4. Muscarinic receptor antagonists for overactive bladder.
Abrams P; Andersson KE
BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
6. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
[TBL] [Abstract][Full Text] [Related]
10. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
12. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
14. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
Chapple CR; Khullar V; Gabriel Z; Muston D; Bitoun CE; Weinstein D
Eur Urol; 2008 Sep; 54(3):543-62. PubMed ID: 18599186
[TBL] [Abstract][Full Text] [Related]
15. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
17. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
Mostafaei H; Salehi-Pourmehr H; Jilch S; Carlin GL; Mori K; Quhal F; Pradere B; Grossmann NC; Laukhtina E; Schuettfort VM; Aydh A; Sari Motlagh R; König F; Roehrborn CG; Katayama S; Rajwa P; Hajebrahimi S; Shariat SF
Eur Urol Focus; 2022 Jul; 8(4):1072-1089. PubMed ID: 34563481
[TBL] [Abstract][Full Text] [Related]
18. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.
Novara G; Galfano A; Secco S; D'Elia C; Cavalleri S; Ficarra V; Artibani W
Eur Urol; 2008 Oct; 54(4):740-63. PubMed ID: 18632201
[TBL] [Abstract][Full Text] [Related]
20. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
